Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816971 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 5
- Study locations
NCT01816971: Active Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma, sponsored by University of Chicago.
NCT01816971 is a Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 76 participants, above the 69-participant average among 4 other Stage III Multiple Myeloma trials with a reported enrollment target (10% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01816971, a Phase 2 study of Stage III Multiple Myeloma and Stage II Multiple Myeloma, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells
Primary Outcome
The percentage of stringent complete response (CR) (sCR) will be reported along with 95% confidence intervals, adjusted for the two-stage nature of the trial design.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG carfilzomib
- PROCEDURE autologous hematopoietic stem cell transplantation
Study Locations (5)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Massachusetts
- Dana Farber - Boston
Missouri
- Washington University in St Louis - St Louis
Tennessee
- Sarah Cannon Cancer Center - Nashville
Ontario
- Princess Margaret - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2013-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What the registry record for NCT01816971 still lists
NCT01816971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 69-participant average among 4 other Stage III Multiple Myeloma trials with a reported enrollment target (10% higher).
The record links to 3 conditions, with Stage III Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01816971 lists 5 locations in 5 states (Illinois, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT01816971 about?
NCT01816971 is a clinical study titled "Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological...
What is the current status of trial NCT01816971?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2013-01. Estimated completion is 2026-12-01.
What conditions does trial NCT01816971 study?
This clinical trial studies the following conditions: Stage III Multiple Myeloma, Stage II Multiple Myeloma, Stage I Multiple Myeloma.
What interventions are being tested in trial NCT01816971?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), lenalidomide (DRUG), carfilzomib (DRUG), autologous hematopoietic stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT01816971?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01816971 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, Missouri, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
COMPLETED · Phase 2
-
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
COMPLETED · Phase 3
-
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia